Background. When using risk prediction models, an important consideration is weighing performance against the cost (monetary and harms) of ascertaining predictors. Methods. The minimum test tradeoff (MTT) for ruling out a model is the minimum number of all-predictor ascertainments per correct prediction to yield a positive overall expected utility. The MTT for ruling out an added predictor is the minimum number of added-predictor ascertainments per correct prediction to yield a positive overall expected utility. Results. An approximation to the MTT for ruling out a model is 1/[P (H(AUC model )], where H(AUC) = AUC -{½ (1-AUC)} ½ , AUC is the area under the receiver operating characteristic (ROC) curve, and P is the probability of the predicted event in the target population. An approximation to the MTT for ruling out an added predictor is 1 /[P {(H(AUC Model:2 ) -H(AUC Model:1 )], where Model 2 includes an added predictor relative to Model 1. Limitation. The latter approximation requires the Tangent Condition that the true positive rate at the point on the ROC curve with a slope of 1 is larger for Model 2 than Model 1. Conclusion. These approximations are suitable for back-of-the-envelope calculations. For example, in a study predicting the risk of invasive breast cancer, Model 2 adds to the predictors in Model 1 a set of 7 single nucleotide polymorphisms (SNPs). Based on the AUCs and the Tangent Condition, an MTT of 7200 was computed, which indicates that 7200 sets of SNPs are needed for every correct prediction of breast cancer to yield a positive overall expected utility. If ascertaining the SNPs costs $500, this MTT suggests that SNP ascertainment is not likely worthwhile for this risk prediction.
Because risk prediction models are often used in medical decision making, there is great interest in improving their performance by incorporating an added predictor (or set of predictors). Predictors could include a biomarker (such as a protein in the blood), a risk factor (such as age), or an imaging result. An important question is whether the increased risk prediction performance from an added predictor is worth the cost (monetary cost and harms) of ascertaining the added predictor. Let AUC denote the area under the receiver operating characteristic (ROC) curve. Let Model 1 denote the basic risk prediction model, and let Model 2 denote a risk prediction model with the same predictors as Model 1 plus an added predictor (or set of predictors). Standard metrics for the statistical evaluation of an added predictor, such as the Division of Cancer Prevention, National Cancer Institute, Bethesda, USA (SGB). Financial support for this study was provided by The National Cancer Institute. The study sponsor had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication.
odds ratio, the difference in the AUC between Model 1 and Model 2, 1 and the net reclassification improvement (NRI), 2, 3 do not address this question. As an example, consider the prediction of the 5-y rate of invasive breast cancer in asymptomatic women. 4 Women at high risk could receive daily tamoxifen or raloxifene pills to lower the risk of breast cancer; although, there are serious side effects to this, including an increased risk of uterine cancer and thromboembolic events. 5 Model 1 involves predictors obtained via questionnaire, such as age and family history of breast cancer. Model 2 adds to the predictors in Model 1 a set of 7 single nucleotide polymorphisms (SNPs). The ascertainment of SNPs involves genotyping blood at a considerable monetary cost. A comparison of Model 2 v. Model 1 yields the following results: the largest odds ratio among the 7 SNPs was 1.35, the AUC increased from 0.56 to 0.59, and the net reclassification improvement based on 3 risk categories (\1.5%, 1.5% to 2%, and .2%) was 0.085. Based on these metrics, the investigators 4 characterized the addition of SNPs to the risk prediction model as a ''modest improvement''. However, these statistical measures do not summarize the tradeoff between the improvement in risk prediction with SNPs and the cost associated with ascertaining the SNPs.
Relative utility curves 6,7 are a decision-analytic approach to evaluating risk prediction. They are related to decision curves 8 but with a different theoretical foundation. Here, the use of relative utility curves to derive the minimum test tradeoff (MTT)-previously called the summary test tradeoff-are discussed. 9 MTT is useful for ruling out a risk prediction model or ruling out an addedpredictor based on the performance of prediction and the cost of ascertaining predictors. The key contributions here are approximations to the MTT that only involve the AUC and the probability of the predicted event in the target population.
Roc and Relative Utility Curves
The starting point is a risk prediction model fit to a training sample. Applying this risk prediction model to a validation sample yields a score for each person in the validation sample. The score should have the property that, in the absence of sampling variability, risk increases as score increases. A basic measure of the prediction performance of the score in the validation sample is the ROC curve. The validation sample should be representative of a target population in the sense that both have the same ROC curves. Let s denote a cutpoint of the score. Let FPR(s) = pr(score . s | no event) denote the falsepositive rate at cutpoint s. Let TPR(s) = pr(score . s | event) denote the true-positive rate at cutpoint s. The ROC curve is a plot of TPR(s) v. FPR(s). Let Risk(s) = pr(event | score = s) denote the risk at cutpoint s. Let P denote the probability of the predicted event in the target population. The slope of the ROC curve is a simple function 7, 9 of P and Risk(s),
See Appendix A for a derivation. Viewing P as a prior probability, ROCSlope(s) as a likelihood ratio, and Risk(s) as a posterior probability, equation (1) is equivalent to the odds ratio formulation of Bayes formula. 10 
Net Benefits
The 3 relevant decision rules are treat-none, treat-all, and treat-from-prediction. Treat-from-prediction at cutpoint s means receiving treatment if the score is greater than s (defined as a positive result) and receiving no treatment if the score is less than or equal to s (defined as a negative result). To evaluate the decision rules, it is necessary to consider benefits and costs. Let B denote the benefit of a true positive, and let C denote the cost (including monetary costs and harms) of a false positive. For the aforementioned example involving the prediction of breast cancer, B is the benefit of reduced breast cancer risk arising from daily pills in a true positive (a woman correctly predicted to develop breast cancer in the absence of the daily pills) and C is the cost of an increased risk of uterine cancers and blood clots arising from daily pills in a false positive (a woman incorrectly predicted to develop breast cancer in the absence of daily pills). An expected utility is the sum of expected benefits minus expected costs (monetary costs and harms), where costs and benefits are in the same units. The motivation behind the following mathematical development is to evaluate decision rules without explicitly specifying the benefits and the costs. The net benefit of treat-from-prediction v. treat-none is defined as the expected utility of treat-from-prediction minus the expected utility of treatnone, which simplifies to:
In terms of population quantities, the net benefit in the decision curve literature 8 equals NBPred TreatNone (s)/ B. The net benefit of treat-from-prediction v. treat-all is defined as the expected utility of treat-from-prediction minus the expected utility of treat-all, which simplifies to:
Equations (2) and (3) follow from more basic equations involving utilities of false and true positives and false and true negatives. 6, 7 See Appendix B for a derivation. The risk threshold T is the risk of the event at which a person would be indifferent between treatment and no treatment. If a person with score s has Risk(s) . T, the person would, by definition, prefer treatment. An important result in the field of decision analysis 11 is C/B = T/ (1-T).
See Appendix C for a derivation. An ROC curve is concave if the slope decreases monotonically from left to right. Another important result in the field of decision analysis 12, 13 is that, for a concave ROC curve, the maximum net benefit of treat-from-prediction v. treat-none or treat-all at risk threshold T occurs at cutpoint s that solves:
See Appendix D for a derivation. Let s opt(T) denote the optimal cutpoint defined as the value of s that solves equation (4) . By definition, the maximum net benefit of treat-from-prediction v. treat-none and treat-all are, respectively:
Relative Utility
Relative utility is the maximum net benefit of treatfrom-prediction divided by the net benefit of treat-fromperfect-prediction:
The net benefits of treat-from-perfect-prediction v. treat-none and treat-all are obtained by substituting TPR(s) =1 and FPR(s) = 0 into the equations (2) and (3) to yield NBPerfectPred TreatNone = P B and NBPerfectPred TreatAll (s) = (1-P) C, respectively. Because the net benefit of treat-from-perfect prediction is less than or equal to the net benefit of treat-fromprediction, and because net benefits are non-negative, 0 RU(T) 1. The relative utility does not include the cost of ascertaining predictors. The treat-none default occurs when the expected utility of treat-none is larger than the expected utility of treat-all, corresponding to T ! P. The treat-all default occurs in the complementary situation corresponding to T \ P. Extensive simplification of equation (7) yields:
Relative Utility Curves
A relative utility curve is a plot of RU(T) v. T. The maximum of the relative utility curve occurs at T = P, with the relative utility curve monotonically decreasing on both sides of T = P. See Appendix E for a proof. Substituting T = P into equation (4) gives the important result that the maximum of the relative utility curve corresponds to the point on the ROC curve where ROCSlope(s opt(P) ) = 1. From equation (8) , the maximum relative utility is:
Construction of a relative utility curve requires only a concave ROC curve and specification of P. Concavity of the ROC curve is needed to ensure that relative utility is based on the maximum net benefit of treat-fromprediction in equation (7). If the original ROC curve is not concave, it is necessary to transform it to a concave ROC curve. For creating a concave ROC curve from a non-concave ROC curve, a piecewise-linear concave envelope of the original ROC curve, as used here, has a decision-analytic optimality. 7 To construct the relative utility curve, it is not necessary to start with T and then compute RU(T).
Instead, a backdoor approach can be used. Each point (with a corresponding FPR, TPR and ROCSlope) on the concave ROC curve corresponds to a point on the relative utility curve. Substituting FPR, TPR and ROCSlope into equation (8) , without explicit specification of s opt(T) , yields RU. Substituting ROCSlope and P into equation (1) yields Risk, which, according to equation (4) is the risk threshold T at the optimal cutpoint. These calculations yield one point (T, RU) on the relative utility curve. Repeating this pair of calculations for various points on the piecewise linear concave ROC curve yields the relative utility curve.
Calibration is the process of adjusting the score (typically when it is a predicted risk) from the training sample to obtain an unbiased estimate of the predicted risk in the target population, which can be compared to the risk threshold for the target population. With relative utility curves, calibration is automatic because Risk in equation (1) applies to the target population via 2 quantities that apply to the target population, ROCSlope and P. Thus, the risk threshold, which equals Risk at the optimal cutpoint in equation (4), applies to the target population. The relative utility, which is a function of the population quantities FPR, TPR and ROCSlope, also applies to the target population. Figure 1 presents ROC and relative utility curves for hypothetical data generated according to the procedure in Appendix F. Figure 2 presents these curves for the aforementioned study involving breast cancer risk prediction. The curves in Figure 2 are not smooth because the data comes from a published table with only 3 categories of risk. 4 The treat-none and treat-all labels in Figures 1  and 2 refer to the regions of the risk threshold where those decisions yield the largest expected utilities.
Ruling Out A Risk Prediction Model
Let ''all-predictor ascertainment'' denote ascertaining all the predictors in the model. Let C model denote the cost of all-predictor ascertainment, which includes the monetary costs of data collection as well as monetary costs and harms of any required tests. The quantity C model is in the same units as B and C. The motivation for the test tradeoff for the model, denoted TestTradeoff model (T), is to draw conclusions about the relationship among C model , B and C, without specifying these quantities.
Let maxNBPred(T) denote either maxNBPred TreatNone (T) or maxNBPred TreatAll (T), depending on whether the default in the absence of risk prediction is treat-none or treat-all. The overall expected utility for the model was defined as the maximum net benefit of treatfrom-prediction minus the cost of all-predictor ascertainment, namely maxNBPred model (T) -C model . A risk prediction model is worthwhile if the overall expected utility is positive, which implies:
where
See Appendix G for a derivation of equation (10) . The ratio B/C model is the number of all-predictor ascertainments per correct prediction. To see this, B is thought of as the price of an apple (benefit of a correct prediction) and C model as the price of an orange (cost of all-predictor ascertainment). Then B/ C model is the number of oranges (all-predictor ascertainments) traded for each apple (correct prediction). The key to understanding TestTradeoff model (T) is that it is a lower bound for B/ C model in equation (10) . Consequently, TestTradeoff model (T) is the minimum number of all-predictor ascertainments per correct prediction of the event to yield a positive overall expected utility at risk threshold, T. The main limitation to applying TestTradeoff model (T) is specifying the risk threshold T. A standard approach to circumvent this limitation is to perform a sensitivity analysis for the test tradeoff over a plausible range of risk thresholds T. 7, 14 However, this sensitivity analysis also has limitations: 1) specifying the plausible range of risk thresholds can be difficult because of insufficient knowledge of preferences, 2) estimating the test-tradeoff at a risk threshold requires individual-level data that may be unavailable, and 3) estimating test tradeoff can be unreliable for extreme values of the risk threshold due to small sample sizes.
Minimum Test Tradeoff for the Model
Investigators can circumvent the limitations of the test tradeoff sensitivity analysis by considering a more limited form of inference, namely ruling out the risk To rigorously rule in a risk prediction model, a maximum of the test tradeoff over a plausible range of risk thresholds is needed, which is difficult to specify. Based on equations (9) and (10),
MTT model is the minimum number of all-predictor ascertainments per correct prediction of the event to yield a positive overall expected utility. The following example illustrates the use of MTT model . Suppose that ascertaining all predictors involves performing sets of expensive genetic tests, the predicted event is not life-threatening, and MTT model = 1000. In other words, a minimum of 1000 sets of expensive genetics tests would be needed for each correct prediction of an event that is not life-threatening to yield a positive overall expected utility. In this context MTT model = 1000 would likely rule out the risk prediction model.
Approximation to the Minimum Test Tradeoff for the Model
Approximating MTT model involves approximating the maximum relative utility, RU model (P) by
Equation (12) is derived using Figure 3 , where point A is the point on the ROC curve with slope =1, f is the falsepositive rate at point A, and h = TPR -FPR at point A. Based on equation (9), h is the maximum relative utility. The ROC curve has an upper bound at line segment GB that is tangential to the ROC curve at point A, so has a slope of 1. The AUC of the upper bound equals 1 -area of DDGB = 1 -½ (1 -h) 2 . The ROC curve has a lower bound at line segments FA and AC. The AUC of the lower bound equals ½ + area of DFAE + area of DACE = ½ + ½ h (1 -f) + ½ h f = ½ + ½ h. Separately solving for h in terms of AUC for the upper and lower bounds and taking the average gives h=H(AUC) in equation (12) . For a variety of ROC curves, the approximate maximum relative utility was close to its exact value (Figure 4 ). Substituting equation (12) into equation (11) yields the approximate MTT for the model,
Ruling Out An Added Predictor
The derivation of the MTT for ruling out an added predictor parallels the derivation of the MTT for ruling out a risk prediction model, but with an added condition. Let C added denote the cost or harm of ascertaining the added predictor with Model 2 in comparison with Model 1. The motivation for the test tradeoff for the added predictor, denoted TestTradeoff added (T), is to draw conclusions about the value of adding a predictor without specifying C added , B, or C. The overall expected utility for the added predictor is defined as the added maximum net benefit of treat-from-prediction in Mode 2 v. Model 1 minus the cost of the added predictor, namely maxNBPred Model:2 (T) -maxNBPred Model:1 (T) -C added . An added predictor is worthwhile if the overall expected utility is positive, which implies:
, for treat-all default,
The ratio B/ C added is the number of added-predictor ascertainments per correct prediction. The key to understanding TestTradeoff added (T) is that it is a lower bound for B/C added in equation (14) . Therefore, TestTradeoff added (T) is the minimum number of added predictor ascertainments per correct prediction to yield a positive overall expected utility at risk threshold T.
Minimum Test Tradeoff for the Added Predictor
The minimum of TestTradeoff added (T) over all possible risk thresholds T is
MTT added is the minimum number of added-predictor ascertainments per correct prediction of the event to yield a positive overall expected utility. The following example illustrates the use of MTT added . Suppose that ascertaining the added predictor involves an invasive test with a high risk for mortality and morbidity, a predicted event of breast cancer incidence, and MTT added = 4000. In other words, a minimum of 4000 high-risk invasive tests would be needed for each correct prediction of breast cancer to yield a positive overall expected utility. In this example, MTT added = 4000 would likely rule out using the result of the invasive test as added predictor.
Approximation to the Minimum Test Tradeoff for the Added Predictor
The first step in approximating MTT added in equation (15) is to substitute the difference in maximum relative utilities for the maximum difference in relative utilities, Figure 5 illustrates the Tangent Condition under the treat-none default (T ! P) but a similar argument would apply to a treat-all default. Based on equation (8) for the treat-none default, namely RU = TPR-ROCSlope FPR, the tangent lines intersect the vertical axis at RU. Points A1 and A2 denote the points on the ROC curves with ROCSlope=1 for Models 1 and 2, respectively. Because ROCSlope=1 corresponds to the maximum relative utility, the tangent line for Point A1 intersects the vertical axis at the maximum relative utility for Model 1, denoted maxRU1. Similarly, the tangent line for Point A2 intersects the vertical axis at the maximum relative utility for Model 2, denoted maxRU2. Points B1 and B2 denote the points on the ROC curves with ROCSlope=2 for Models 1 and 2, respectively. RU1b and RU2b denote the relative utilities at which the tangent lines for Points B1 and B2 intersect the vertical axis. Geometrically, the Tangent Condition says that Point A2 is higher than Point A1. In many cases, the Tangent Condition implies a steeper ROC curve between Points A and B for Model 2 than Model 1, which typically implies maxRU2 -maxRU1 is larger than RU2b -RU1b, as in Figure 5 . See Appendix H for the exact conditions for maxRU2 -maxRU1 to be larger than RU2b -RU1b. The exact conditions are harder to check than the Tangent Condition, which is why the Tangent Condition is presented instead.
To more fully investigate the Tangent Condition, 8 panels of ROC and relative utility curves in Figure 6 were considered. In panels (A) to (D), the Tangent Condition holds: DRU(P) is the largest difference between the relative utility curves, and hence MTT added(difmax) equals MTT added . In panels (E) and (F), the Tangent Condition holds: DRU(P) approximates the largest difference between the relative utility curves, and hence MTT added(difmax) approximates MTT added . In panels (G) and (H), the Tangent Condition does not hold: DRU(P) is substantially smaller than the largest difference between the relative utility curves, and hence MTT added(difmax) poorly approximates MTT added .
The next step to approximating equation (15) is to substitute equation (12) 
Examples
Visual inspection of the ROC curve in Figure 1 shows that the Tangent Condition holds. For Figure 1 with P = 0.2, MTT added(approx) = 88, which is close to the exact value of MTT added = 101. Visual inspection of the ROC curve in Figure 2 also suggests that the Tangent Condition holds. For Figure 2 with P = 0.003, MTT added(approx) = 7200, which is close to the exact value of MTT added = 7500. In other words, based on the approximation, it is necessary to measure 7200 sets of SNPs for every correct prediction of breast cancer to yield a positive overall expected utility. If ascertaining SNPs costs $500, MTT added(approx) = 7200 suggests that SNP ascertainment is not worthwhile.
Discussion
If individual-level or count data are available, investigators can use software written in Mathematica to compute concave ROC curves, relative utility curves, and the entire test tradeoff curve (See https://prevention.cancer.gov/aboutdcp/staff-search/stuart-g-baker-scd/evaluating-risk-prediction).
The main purpose of the approximation to the MTT is a back-of-the envelope calculation based on limited reported data. Before computing the approximation to MTT (either for the model or added predictor), one should check that the ROC curve is concave or almost concave. Small deviations from the ROC curve concavity should have little effect on conclusions, whereas large deviations from concavity could introduce substantial bias. If there are large deviations from concavity, the risk prediction Figure 5 A visual example of the Tangent Condition (Point A2 higher than Point A1) implying that the difference in maximum relative utilities (maxRU2-maxRU1) is the maximum difference in relative utilities. Figure 6 The Tangent Condition holds in all panels, except (G) and (H). When it holds, the difference in maximum relative utilities (at T = P) equals or approximates the maximum difference in relative utilities. model is poor (as risk does not monotonically increase with the score) and should not be used.
There is no guarantee that the Tangent Condition will always yield a good approximation for the MTT for the added predictor but it was a reasonable condition in the examples in Figure 6 . For perspective, one should realize that, even with the entire test tradeoff or relative utility curve, the determination of MTT involves some judgment as to whether the minimum of a test tradeoff that does not occur at the T= P occurs at a plausible risk threshold. Also, one should appreciate the importance of correctly specifying the probability of the predicted event in the target population. Particularly when the probability of a predicted event is small, as, when the predicted event is cancer incidence, MTT can be sensitive to this probability and investigators may wish to perform a sensitivity analysis involving this probability.
Remarkably, the approximation to the MTT involves the AUC, a quantity that does not contain information on costs and benefits. The intuition is that the MTT depends on the maximum relative utility, which corresponds to a slope of 1 on the ROC curve at a point that visually anchors the entire ROC curve. In summary, if published results from risk prediction analyses report only ROC curves and AUCs, the approximation to the MTT is useful for a back-of-the-envelope calculation for evaluating a risk prediction model or added risk predictor(s) relative to the cost of predictor ascertainment. This approximation to MTT is preferential to standard metrics that do not consider the tradeoffs between improved prediction and the cost of predictor ascertainment.
